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Objectives: To compare the effectiveness and safety of balloon aortic valvuloplasty
(BAV) performed with or without rapid ventricular pacing (RP).
Background: BAV technique is poorly standardized.
Methods: One hundred consecutive patients were randomly assigned 1:1 between
BAVperformedwith orwithout RP. Exclusion criteriawere an immediate indication for
surgical or transcatheter aortic valve replacement, presentation in cardiogenic shock or
pulmonary edema refractory to medical stabilization.
Results: There were 51 patients in the BAV group performed with RP, 49 in the BAV
group without RP (noRP). Procedural success (50% hemodynamic gradient reduction)
was achieved in 37.3% and 55.1%, respectively (P = 0.16). Fewer people in the noRP
group complained of poor tolerance to the procedure (16% vs 41%). The primary
efficacy endpoint, a 50% reduction in themeanechocardiographic trans-aortic gradient,
was met in 21/49 patients in the noRP group compared to 20/51 in the RP (42.9% vs
39.2%; P = 0.84). No significant difference between the groups was observed in the
primary safety endpoint, a 30-day composite of death, myocardial infarction, stroke,
acute aortic regurgitation, and BARC bleeding ≥3 (8.2% noRP vs 13.7%; P = 0.53). The
noRP group required fewer bailout temporary pacemakers (P = 0.048) and had a lower
incidence of moderate/severe renal function worsening (4.1% vs 17.6%; P = 0.052).
Conclusions: Rapid ventricular pacing did not influence BAV efficacy or safety and
tolerance was slightly worse.
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1 | INTRODUCTION
In the last decade, alongside the development and consolidation of
transcatheter aortic valve replacement (TAVR),wewitnessed a renewed
interest in percutaneous balloon aortic valvuloplasty (BAV), demon-
strated by a considerable increase in the number of procedures
performed worldwide.1,2 Recent data suggest a lower incidence of
complicationsduringBAV incomparison to the initial experiencesdating
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back to the eighties.3,4 However, several technical aspects of BAV have
never been standardized and are currently left to the operator's
preference.5 Variability includes, among others, balloon sizing, vascular
sheath size and hemostasis, and the definition of procedural success.
Rapid ventricular pacing (RP) is commonly used during balloon
inflation to obtain temporary circulatory arrest and help stabilize the
balloon within the valve orifice. Yet, in expert hands, BAV can be
performed without RP with an overall less invasive and possibly better
tolerated approach. To date, there are no direct comparisons between
BAVperformedwith orwithout RP in terms of safety and effectiveness.
Registrydata suggest similarprocedural safety in the two techniquesbut
less efficacy in the RP technique, in terms of a smaller post-procedural
aortic valve area (AVA), despite easier balloon stabilization.6
Our study sought to compare the effectiveness and safety of BAV
in a randomized setting performedwith or without RP in an unselected
patient population.
2 | MATERIALS AND METHODS
2.1 | Patient population
This is a prospective, open-label, randomized study with the purpose of
enrolling 100 consecutive patients with severe degenerative aortic
stenosis (AS) undergoing BAV at the S.Orsola-Malpighi University
Hospital inBologna.The studyprotocolwasapprovedby the local Ethics
Committee (CE41/2015/O/Sper) and published on clinicaltrials.gov
(NCT02498639). Patients 70 years of age or older, affected by severe
symptomatic AS and with an indication for BAV were eligible. The
indication for BAV was independent from the present study and
preceded enrollment. Exclusion criteria were an immediate indication
for surgical aortic valve replacement (AVR) or TAVR, clinical presenta-
tion in cardiogenic shock or pulmonary edema refractory to medical
stabilization. Before enrollment, all patients were required to sign an
informed consent to adhere to the study procedures and allow their
personal data tobeprocessed. Theywere then1:1 randomly assigned to
undergo BAV with or without rapid cardiac pacing. Randomization was
doneusing specific software after patients signed the informedconsent.
Of note, enrollment in the study did not exclude a subsequent final
treatment of the aortic valve disease via TAVR or AVR.
Before BAV, all patients received an echocardiography scan to
specifically check, among other parameters, the left ventricle ejection
fraction (LVEF), the left ventricle outflow-tract diameter (LVOT), the
aortic annulus, the maximum and mean trans-aortic gradients (ΔP), the
aortic valve area (AVA) calculated by the continuity equation, the
indexed AVA (AVA/BSA), and the aortic regurgitation grade. Ultra-
sound measurements were collected according to the American
Society of Echocardiography and the European Association of
Cardiovascular Imaging recommendations.7
2.2 | Balloon aortic valvuloplasty procedure
Percutaneous balloon aortic valvuloplasty was performed through the
left or right femoral artery, where a 9 or 10 Fr vascular sheath (Cordis
Corporation, Fremont, CA) was placed, depending on the size of the
selected balloon catheter. All procedures were performed with the
semi-compliant Cristal Balloon™ (BALT Extrusion SAS, Montmorency,
France). All patients received a low dose bolus of intravenous
unfractioned heparin (30-50 IU/kg). The retrograde crossing of the
aortic valve was achieved with a 0.035″ straight wire within an
Amplatz AL1 catheter. After crossing the valve orifice, a 0.038″ extra
stiff wire with a handmade loop at its distal tip was placed into the left
ventricle. To minimize the pressure recovery phenomenon when
measuring the hemodynamic gradient, instantaneous mean hemody-
namic trans-aortic gradient (ΔP) was measured with two 4 Fr pigtail
catheters, one in the left ventricle and the other in the ascending aorta
(central ΔP). Additionally, the instantaneous gradient between the
ventricular pigtail and the side port of the vascular sheath (peripheral
ΔP) was available and collected to check for possible differences with
the central measurement, but was not considered for interruption
criteria (see below). Both pigtails, by virtue of their small size, were
inserted within the same femoral vascular sheath.
After gradient measurement, the balloon was advanced within the
valve over the extra stiff wire and inflated with a mixed solution of
contrast dye and saline. The same inflation system was used in both
groups, consisting of a “volumetric” syringe (50mL), which initially fills
the balloon, and a “pressure” syringe (10mL), both connected to a
manometer through a deflection valve. In the group randomized for
RP, a temporary flow-directed unipolar pacing catheter (Pacel™, St.
Jude Medical Inc., St Paul, MN) was positioned in the right ventricle
through a 6 Fr vascular sheath (St. Jude Medical) placed in the
ipsilateral femoral vein. Ventricular pacing at 180-200 bpm rate was
started just before balloon inflation and stopped at the time of
deflation, for a maximum duration of 10 s. In the group randomized for
BAVwithout RP, the ventricular contractions compromise the stability
of the balloon during inflation, facilitating slippage towards the aorta or
the ventricle chamber. Balloon stabilization at the level of the valve
orifice was obtained by balancing the thrust forces exerted on the
extra stiff wire inside the left ventricle and those exerted on the
balloon pushed over the wire.
The pressure line connected to the side port of the vascular sheath
allowed systemic pressure to be monitored during the entire
procedure. Generally, when rapid pacing is not used, normal pressure
wave oscillations become damped during balloon inflation. In the event
of complete aortic pulse abrogation, the operator can infer that the
inflated balloon almost completely seals off the valve orifice, and can
thereby avoid further increasing inflation volume and pressure
(Figure 1A). Likewise, for safety reasons, the operator is discouraged
from upgrading balloon size even in the presence of a suboptimal
procedural result. When rapid pacing is applied, the pressure curve is
abolished due to deliberately ineffective contractions and so the
operator cannot rely on the sealing concept (Figure 1B).8
To prevent possible bias from influencing the efficacy or safety of
either technique due to potentially applying different inflation
pressures, three inflations were planned for each patient in both
branches of the trial, always at nominal balloon pressure (checked via
manometer), afterwhich the trans-aortic gradientwasmeasured again.
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Moreover, the duration of iatrogenic hypotension, due to valve
sealing or RP, per protocol was sustained for 10 s (less only if poorly
tolerated) in both branches of the study. Balloon size was initially
chosen according to the aortic valve annulus measured at
echocardiography:7
 annulus ≤ 19mm→ balloon diameter 18mm
 annulus 20-23mm→ balloon diameter 20mm
 annulus ≥ 24mm→ balloon diameter 23mm
After the first sequence of three inflations, the procedure was
terminated if one of the following criteria was met:
1 Procedural success, defined as 50% reduction of the mean trans-
aortic gradient (hemodynamic measurement);
2 Procedural complication (ie, cardiac tamponade, acute aortic
insufficiency, etc.)
3 Poor patient tolerance to the procedure (malaise, overt intolerance),
in particular during balloon inflation and rapid pacing, or worsening
of the vital parameters (ie, changes in pressure wave, electrocardio-
gram, O2 arterial saturation).
Additional interruption criteria were:
4 In case of BAV without RP, aortic pressure drop due to the inflated
balloon sealing off the valve annulus (confirming achievement of a
1:1 balloon-to-annulus ratio, hence no benefit expected from
upgrading balloon size) as shown in Figure 1A;
5 In case of BAV under RP, observing the aortic annulus footprint on
the balloon profile during full balloon expansion (confirming
achievement of at least a 1:1 balloon-to-annulus ratio, hence no
benefit expected from a larger balloon) as shown in Figure 1C.
When none of the above criteria was met, a second series of three
inflations was performed with a larger diameter balloon. Only one
balloon upgrade was allowed per protocol. An 8 Fr Angio-Seal™ (St.
Jude Medical, St. Paul, MN) was used for arterial hemostasis, whereas
manual compressionwas applied to the venous access site. All patients
received a compressive bandage for 24 h of bed rest. This study was
conducted according to the Declaration of Helsinki.
2.3 | Endpoints and definitions
The primary efficacy endpoint, in an intention to treat analysis, was a
50% reduction in the mean trans-aortic gradient measured by
echocardiography 30min after BAV.
Valve Academic Research Consortium-2 definitions were used to
classify the in-hospital and follow-up complications, whereas Bleeding
Academic Research Consortium (BARC) definitions were specifically
applied for bleedings.9,10 The primary safety endpoint was the
composite of death, myocardial infarction (MI), stroke, acute aortic
regurgitation, and BARC bleeding ≥3 collected at 30-day follow-up.
FIGURE 1 (A) Printing of the pressure curve during aortic valvuloplasty at the moment of balloon inflation; (B) image from the polygraph at
the time of rapid ventricular pacing preceding balloon inflation; (C) inflated balloon at the valve orifice level, with a visible footprint on its
sides given by the calcified valve annulus and leaflets
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Secondary endpoints were: a 50% reduction in the mean trans-
aortic gradient measured via echocardiography 30min after BAV in a
per-treatment analysis; a gradient reduction of 30-49%; reduction of
the mean invasive hemodynamic gradient ≥ 50% and in the 30-49%
range; the 30-day rate of all-cause death, cardiovascular death, stroke,
myocardial infarction, major bleeding (BARC ≥3), evaluated individu-
ally; all vascular complications (VARC-2 definitions); procedural acute
aortic insufficiency, procedural acute kidney injury (VARC-2); length of
hospital stay; increase in AVA echocardiography post-BAV; poor
tolerance to the procedure subjectively reported by the patient;
comparison of Numeric Rating Scale for Pain (NRS) questionnaire
data.11 Outpatient clinic visits were scheduled for 30-day follow-up
and data were collected via telephone if the visit was not possible.
2.4 | Statistical analysis
Continuous variables are illustrated as mean ± standard deviation and
compared via the t-Student test. Categorical variables are shown as
absolute number and percentage. The differences between the groups
were analyzed using the Chi-square tests or the Fisher's Exact test
when appropriate. A P-value <0.05 was considered statistically
significant. All analyses were performed with SPSS Statistic, version
17.0 (SPSS Inc., Chicago, IL).
3 | RESULTS
Starting in April 2015, 128 consecutive patients with severe
symptomatic aortic valve stenosis referred to our hospital were
evaluated for study eligibility. Figure 2 shows the study flow chart.
We collected 28 cases of screening failure mainly due to denial of
consent for the study (n = 16), while some cases failed screening
because of dementia (n = 3), difficulty in comprehending Italian
(n = 1), rheumatic aortic valve stenosis (n = 2), emergency procedure
or very poor global status (n = 2), patients coming from other
hospitals with risk of incomplete follow-up (n = 4). One hundred
patients were enrolled in the study and randomized 1:1 so that 49
were assigned to the No-RP group and 51 to the RP group. All
patients underwent the assigned procedure, resulting in the
“intention-to-treat” and “per-treatment” analysis coinciding. Baseline
characteristics, clinical presentation and echocardiography data did
not differ between the groups (Table 1).
3.1 | Procedural data
The main baseline hemodynamic parameters at univariate analysis
were similar between the groups as well at the end of the entire
procedure (Figure 3). Furthermore, this picture shows that the mean
aortic and femoral pressure values were similar, hence in our
population the pressure recovery phenomenon was trivial. Because
the baselinemean gradient between aortic and femoral artery pressure
was between 5 and 4.3 mmHg in the two groups, we assumed that our
decision to rely on the LV-Aortic (for the hemodynamic endpoints and
decision making) did not bring to different results in comparison to the
eventual use of the LV-femoral artery gradient. As reported in Table 2,
the first series of inflations was more frequently performed with a
20mm balloon both in the No-RP (38/49, 77.6%) and in the RP group
(41/51; 80.4%). Of note, the balloon/annulus diameter ratio,
calculated as the ratio between the nominal balloon size and the
echocardiographic measurement of the aortic annulus, was equivalent
(0.92 vs 0.93; P = 0.12).
After the first series of inflations, procedural successwas achieved
in 15 out of 51 patients in the RP population compared with 20 out of
49 among those without RP (29.4% vs 40.8%; P = 0.30) (Table 3).
In the latter group, despite mean gradient halving not being met in
29 (59.2%) patients, only 10 underwent a second series of inflations
with a bigger size balloon. The upgrade to a bigger balloon was not
performed 16 times because aortic valve sealing was obtained
(predefined no upgrade criterion), whereas in the remaining three
cases, the reasons were: balloon rupture and entrapment at the
vascular sheath requiring recapture by a lazo; ventricular fibrillation
treated by DC-shock; subjective intolerance to the procedure. When
the balloon upgrade was performed, aortic valve sealing was always
met. In the RP group, the upgrade to a bigger balloon size was required
in 36 cases (70.6%), but only actually performed in 19. Lack of balloon
upgrade in 17 patients was due to: very poor patient tolerance (n = 6);
prolonged hypotension after RP (n = 4); severe bradycardia or high
grade A-V block (n = 3); atrial fibrillation with fast ventricular rate
(n = 1); transient acute aortic regurgitation (n = 1); chest discomfort
FIGURE 2 Study flow chart
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(n = 2). The balloon/annulus ratio remained comparable between the
groups after diameter upgrade (1.0 vs 1.0; P = 0.30).
Final halving of the hemodynamic gradient was met in 26/49
patients in the No-RP and 19/51 in the RP group (55.1% and 37.3%,
respectively; P = 0.16). Mean trans-valvular gradient decreased
similarly and did not differ between the groups either before or after
the first or second series of inflations (Figure 4).
Overall, significantly fewer patients who underwent BAV without
RP complained of poor tolerance to the procedure than those with RP
(16% vs 41%, respectively, P < 0.05). No differences in the sensation of
pain were collected with the NRS questionnaire. Use of procedural
antithrombotics was similar between the two groups. Equivalent
percentages of patients underwent concomitant angiographies and
percutaneous coronary revascularization procedures and, as such, the
total amount of contrast dye was also equivalent between the two
populations.
3.2 | Primary endpoints
The primary efficacy endpoint, given by a 50% reduction of the
echocardiographic mean trans-valvular gradient, was met in 21/49
patients in the No-RP group compared to 20/51 in the RP group
(42.9% vs 39.2%; P = 0.84). The primary safety composite endpoint
given by the sum of death, myocardial infarction, TIA/stroke, acute
aortic regurgitation, BARC bleeding ≥3 did not differ between the
groups (8.2% for No-RP vs 13.7% for RP; P = 0.53) or any of its
individual components (Table 4).
3.3 | In-hospital clinical complications
Table 4 reports the overall safety outcomes. Of note, we found there
was a significantly higher frequency in the RP population to maintain
the temporary pacemaker post-BAV as compared to the No-RP
population, while no one required a bailout implantation (P = 0.048).
Likewise, albeit not statistically relevant, more permanent pacemakers
were implanted in the RP group (0% vs 5.9%; P = 0.09). No differences
appeared regarding the other main in-hospital complications, in
particular any bleeding, vascular access complications, TIA/stroke,
acute MI, acute aortic regurgitation, pericardial effusion. Moderate to
severe worsening of renal function was similar, but numerically fewer
patients in the No-RP group suffered from transient mild worsening
(4.1% and 17.6% respectively; P = 0.052).
Finally, two patients died during hospital admission in the RP
group, none in the No-RP (P = 0.17). One death was due to cardiac
TABLE 1 Baseline characteristics
No Pacing n = 49 Pacing n = 51 P
Age,years 82.5 ± 5.5 83.3 ± 7.2 0.52
Male gender 23 (46.9) 25 (49.0) 0.84
BSA,m2 1.8 ± 0.2 1.7 ± 0.2 0.23
Diabetes mellitus 11 (22.5) 14 (24.4) 0.38
Hypertension 41 (83.7) 41 (80.4) 0.80
COPD 9 (18.4) 8 (15.7) 0.79
Peripheral artery disease 4 (8.2) 12 (23.5) 0.06
Carotid disease 6 (12.2) 9 (17.6) 0.58
Previous TIA/stroke 4 (8.1) 6 (11.8) 0.79
Previous MI 11 (22.4) 13 (25.5) 0.82
Previous PCI 6 (12.2) 7 (13.7) 1.00
Previous CABG 1 (2.0) 3 (5.9) 0.33
Previous valve surgery 3 (6.1) 4 (7.8) 0.74
Previous BAV 8 (16.3) 6 (11.8) 0.57
Significant CAD 23 (46.9) 22 (43.1) 0.84
Hemoglobin,g/dL 12.2 ± 1.7 11.7 ± 1.7 0.12
GFR <30mL/min 8 (16.3) 14 (28.0) 0.23
Dialysis 0 (0.0) 2 (3.9) 0.16
Clinical presentation
NYHA III-IV 33 (67.3) 33 (64.7) 0.84
Pulmonary edema 2 (4.1) 8 (15.7) 0.09
Angina pectoris 6 (12.2) 8 (15.7) 0.78
Acute coronary
syndrome
4 (8.2) 4 (7.8) 0.95
Syncope 11 (22.4) 12 (23.5) 1.00
Asymptomatic 1 (2.0) 3 (5.9) 0.33
ECG
Atrial fibrillation 14 (28.6) 7 (13.7) 0.09
PR interval, msec 192.2 ± 46.0 175.2 ± 36.0 0.08
QRS interval, msec 118.0 ± 34.8 118.4 ± 28.3 0.89
LBBB 7 (14.3) 10 (19.6) 0.60
RBBB 4 (8.2) 9 (17.6) 0.24
Permanent pacemaker 6 (12.2) 3 (5.9) 0.27
Echocardiography
LVEDV, mL 102.3 ± 41.2 99.5 ± 39.2 0.71
LVEF, % 56.9 ± 14.7 54.2 ± 14.8 0.38
Aortic annulus, mm 22.6 ± 1.6 22.0 ± 1.2 0.07
Aortic mean 44.5 ± 16.0 45.2 ± 16.2 0.77
ΔP, mmHg 73.5 ± 24.0 72.5 ± 24.8 0.84
Aortic max ΔP, mmHg 0.7 ± 0.1 0.7 ± 0.2 0.73
AVA, cm2 1 (2.0) 3 (5.9) 0.33
Moderate-severe AR 2 (4.1) 0 (0.0) 0.15
Moderate-severe MR 47.1 ± 16.7 40.7 ± 10.7 0.06
PAP, mmHg
STS-PROM score, % 4.6 ± 3.7 6.6 ± 6.5 0.06
EuroSCORE II, % 6.0 ± 5.7 6.1 ± 3.6 0.92
Continuous variables are expressed as mean ± SD; categorical variables as
number (%). AR, aortic regurgitation; AVA, aortic valve area; BAV, balloon
aortic valvuloplasty; BMI, body mass index; BSA, body surface area; CABG,
coronary artery bypass graft; CAD, coronary artery; COPD, chronic
obstructive pulmonary disease; ΔP, pressure gradient; GFR, glomerular
filtration rate; LBBB, left bundle branch block; LVDEV, left ventricle end-
diastolic volume; LVEF, left ventricle ejection fraction; MI, myocardial
infarction; MR, mitral regurgitation; NYHA, New York Heart Association;
PAP, pulmonary artery pressure; PCI, percutaneous coronary intervention;
RBBB, right bundle branch block; STS-PROM, Society of Thoracic Surgeons
—probability of mortality; TIA, transient ischemic attack.
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arrest in an 88-year-old woman admitted with pulmonary edema,
severe renal failure and severe left ventricle dysfunction, a Euro-
SCORE II of 16% and STS risk of mortality of 38%. The second
patient who died was an 84-year-old frail diabetic man, admitted in
NYHA functional class IV, with a EuroSCORE II of 7% and STS of 7%.
BAV was preceded by PCI and then complicated by procedural MI
with prolonged bradycardia and hypotension. In comparison to the
in-hospital outcome, at 30-day follow-up, we collected one death in
the No RP group about 2 weeks after discharge, and one stroke in
the RP group.
3.4 | Other echocardiographic results
After BAV, no differences appeared between the groups regarding
final AVA (P = 0.34), average AVA increase (0.27 vs 0.24mm; P = 0.39),
as well as the absolute value of themean trans-valvular gradient and its
reduction percentage (44.8% vs 44.3%, P = 0.87).
4 | DISCUSSION
This study shows no significant differences in the efficacy of
percutaneous balloon aortic valvuloplasty performed either with or
without rapid cardiac pacing. Moreover, the primary safety endpoint
was similar between the two techniques.
We decided to focus on the BAV technique, aware that TAVR
has clearly demonstrated its superiority over BAV in the treatment of
aortic valve disease.12 On the other side, we believe that BAV will
maintain a role in the management of some patients with aortic
stenosis in particular those with: hemodynamic instability at
presentation, relevant frailty, doubtful symptoms (COPD, reduced
mobility, etc. . .) and so a weak initial indication for TAVR. The
incoming extension of TAVR indication to moderate risk patients,
and its not negligible costs, will maintain BAV an option for very old,
frail, and high-risk patients.13 Furthermore, we confirm that
enrollment in this study did not prevent patients from accessing a
future TAVR or AVR treatment.
The BAV procedure has received renewed interest in the last
decades.14 Despite the fact that the first cases date back to about
30 years ago, several aspects of the procedure itself are not well
defined or standardized.5,15,16 The concomitant use of rapid cardiac
pacing to help balloon stabilization has been adopted in most centers,
while BAV is performed without in others. In the absence of a direct
comparison between the two techniques, we sought to evaluate the
influence of RP on procedural efficacy and safety in a randomized and
rigorous study. As the design of the study enrolled amere 100 patients
FIGURE 3 Comparison between the groups of aortic, femoral, and ventricular pressures. At the superior level, the first comparison on the
left is between aortic and femoral pressure, showing no significant difference between central and peripheral arterial pressure: this means
that both values could have been used to calculate the trans-aortic gradient with respect to the left ventricular pressure (in the study we refer
to the difference between LV and aortic pressure as the mean hemodynamic gradient)
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at a single center (the number is only relatively small for a single center
study, in consideration of the amount of BAV performed worldwide
per center), this analysis can be considered hypothesis generating and
a potential basis for sample size calculation in a larger, multi-center
trial, enrolling more patients with shorter recruitment time.
We defined an echocardiographic endpoint as primary efficacy
comparison, obtained by measuring the trans-aortic gradient about
30min after the end of the procedure.We believe that this parameter,
collected shortly after BAV, may be more reliable than the procedural
success evaluated via hemodynamic measurement immediately after
balloon inflation. In fact, BAV generates short phases of hypotension
and stress in patients, which can lead to a reaction characterized by a
release of catecholamines, tachycardia, and increased contractility.
This is often evident when transient phases of high blood pressure are
observed just after the maneuver and, as such, the mean trans-aortic
gradient may be acutely overestimated. Thirty minutes was elected as
a reasonable time frame to allow for full hemodynamic stabilization
after procedural stress or transient complications.
In this study, we must acknowledge a slightly smaller percentage
of success compared to previous reports, defined as a 50% reduction
of the trans-aortic gradient.2 We would like to highlight that the study
protocol mandated balloon inflation at a nominal pressure, so as not to
determine any bias between the groups. At our institute, BAV was
usually performed without RP, allowing the operator to adapt inflation
pressure upon aortic valve sealing, at times even over-expanding the
balloon.8 The predefined less aggressive approach adopted in this trial
might have influenced the final efficacy outcome.
Although not significantly, success in terms of both hemodynam-
ics and echocardiography was numerically more frequent in the No-RP
group. This trend is in line with a previous observation byWitzke et al.6
A contribution to the final result may have come from the more
TABLE 2 Procedural and hemodynamic data
No pacing n = 49 Pacing n = 51 P
Balloon size at 1st
inflations, mm
20.7 ± 1.3 20.5 ± 1.2 0.46
18mm 0 (0.0) 1 (2.0)
20mm 38 (77.6) 41 (80.4)
23mm 11 (22.4) 9 (17.6)
Balloon/annulus ratio at
1st inflations
0.92 ± 0.04 0.93 ± 0.05 0.12
Sealing yes 33 (67.3)
Sealing/pacing duration
First inflation, sec 10.6 ± 2.6 10.3 ± 1.0
Second inflation, sec 10.2 ± 2.6 10.0 ± 0.8
Third inflation, sec 9.7 ± 1.8 9.5 ± 1.1
Balloon size at upgrade,
mm
23.4 ± 0.8 23.3 ± 0.7 0.79
23 8/10 (80.0) 16/19 (84.2)
25 2/10 (20.0) 3/19 (15.8)
Balloon/annulus ratio at
upgrade
1.0 ± 0.1 1.0 ± 0.0 0.30
Sealing yes (upgrade) 10/10 (100.0)
Sealing/pacing duration
(upgrade)
First inflation, sec 9.4 ± 1.7 10.3 ± 1.0
Second inflation, sec 9.7 ± 1.0 10.0 ± 0.8
Third inflation, sec 9.0 ± 2.1 9.5 ± 1.2
Concomitant iliac and
aortic study
33 (67.3) 30 (58.8) 0.41
Concomitant PCI 8 (16.3) 8 (15.7) 1.0
Total contrast dye,ml 60.9 ± 47.9 56.3 ± 47.6 0.63
Procedure duration,
min
87.2 ± 24.5 89.3 ± 27.5 0.68
Procedural drugs
ASA 23 (47.9) 30 (58.8) 0.32
Clopidogrel 7 (14.6) 5 (9.8) 0.55
Clopidogrel Load 7 (14.6) 6 (11.8) 0.77
OAT 17 (35.4) 13 (25.5) 0.38
Heparin 48 (98.0) 51 (100.0) 0.55
Poorly tolerated BAV 8 (16.3) 21 (41.2) <0.05
NRS questionnaire 2.5 ± 2.4 3.1 ± 2.5 0.58
Continuous variables are expressed as mean ± SD; categorical variables as
number (%). ASA, acetylsalicylic acid; BAV, balloon aortic valvuloplasty;
OAT, oral anticoagulant therapy; NRS, Numeric Rating Scale for Pain; PCI,
percutaneous coronary intervention.






































Categorical variables as number/total (%). BAV, balloon aortic
valvuloplasty.
FIGURE 4 Comparison between the groups of the hemodynamic
gradient across the procedural steps
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frequent balloon upgrade in the population without pacing, justified by
a better tolerance to the procedure both in terms of perceived feeling
(patient-reported), and in terms of fewer hemodynamic and rhythm
disorders. Yet, we believe that the perception of annular sealing when
no rapid pacing is used may be helpful in achieving the best benefit-to-
risk ratio for potential balloon upgrades. In fact, due to its frequently
elliptical shape, accurate aortic annular sizing would require a CT scan,
which is rarely used before BAV.
Our data did not show any differences in terms of significant
safety outcomes between the techniques. However, some individual
parameters slightly favored the No-RP group, such as the need for
pacing support after BAV and a trend towards a lower incidence of
transient acute mild kidney injury. These episodes might incur a more
pronounced hemodynamic imbalance during RP rather than the
controlled hypotensive phases observed during BAV without pacing.
In any case, in the absence of any compelling evidence in favor of either
technique, interventional cardiologists are encouraged not to change
their usual BAV procedural practice.
4.1 | Other limitations
At our center, operators more frequently perform BAV without RP,
thus we cannot completely exclude that this may have influenced
the procedural outcome. In this case, multi-center enrollment would
also prevent this potential bias. A primary safety composite endpoint
was chosen to collect a sufficient number of events in consideration
of the overall population enrolled. In particular, we included
bleedings to study whether the different vascular access approach
in each group (a single artery puncture in the No-RP group, a
systematic venous plus arterial puncture in the RP group) could have
influenced the outcome.
The semi-compliant balloons used in this study are widely used in
Europe. Comparing other available devices with different character-
istics (ie, non-compliant, 8-shaped) and/or dedicated to BAV without
RP is certainly a source of further study in this field.
5 | CONCLUSION
In this randomized pilot trial, rapid ventricular pacing did not influence
BAV efficacy or safety. However, BAV without RP would seem to




n = 51 P
Primary efficacy endpoint (50%
gradient reduction)
21 (42.9) 20 (39.2) 0.84
Primary safety composite
endpoint (30-day)
4 (8.2) 7 (13.7) 0.53
Death 1 (2.0) 2 (3.9) 0.58
Myocardial infarction 0 (0.0) 2 (3.9) 0.16
TIA/stroke 0 (0.0) 1 (2.0) 0.31
Acute aortic regurgitation 3 (6.1) 2 (3.9) 0.61
BARC bleeding ≥3 0 (0.0) 2 (3.9) 0.16
In-hospital complications/
events
TIA/Stroke 0 (0.0) 0 (0.0)
AMI 0 (0.0) 2 (3.9) 0.16
AAR 3 (6.1) 2 (3.9) 0.61
Pericardial effusion 0 (0.0) 2 (3.9) 0.16
Cardiac tamponade 0 (0.0) 1 (2.0) 0.33
Emergency surgery 0 (0.0) 0 (0.0)
Temporary PM implantation
bailout
0 (0.0) 4 (7.8) 0.048
Bleedings
BARC ≥3 0 (0.0) 2 (3.9) 0.16
RBC transfusion 0 (0.0) 1 (2.0) 0.33
BARC 1-2 5 (10.2) 2 (3.9) 0.22
Access site complications
Hematoma 3 (6.1) 3 (5.9) 0.96
Arterial-venous fistula 0 (0.0) 0 (0.0)
Pseudoaneurysm 1 (2.0) 0 (0.0) 0.31
Femoral dissection 0 (0.0) 0 (0.0)
Peripheral embolization 0 (0.0) 0 (0.0)
Angio-Seal failure 1 (2.0) 1 (2.0) 0.98
Acute kidney injury
AKI 1 2 (4.1) 9 (17.6) 0.052
AKI 2 0 (0.0) 0 (0.0)




1 (2.0) 1 (2.0) 0.98
Permanent PM
implantation
0 (0.0) 3 (5.9) 0.09
New LBBB 1 (2.1) 2 (4.1) 0.57
New RBBB 0 (0.0) 1 (2.0) 0.32
Death 0 (0.0) 2 (3.9) 0.17
Other echo data post BAV
Max gradient, mmHg 39.1 ± 13.4 40.8 ± 16.2 0.57
Mean gradient, mmHg 24.4 ± 8.7 25.3 ± 11.0 0.68
Delta mean gradient
reduction, %
44.8 ± 13.4 44.3 ± 12.0 0.87






n = 51 P
AVA, cm2 0.98 ± 0.2 0.94 ± 0.2 0.34
AVA improvement, cm2 0.27 ± 0.2 0.24 ± 0.1 0.39
Continuous variables are expressed as mean ± SD; categorical variables as
number (%). AAR, acute aortic regurgitation; AKI, acute kidney injury; AMI,
acute myocardial infarction; AVA, aortic valve area; BARC, Bleeding
Academic Research Consortium; BAV, balloon aortic valvuloplasty; LBBB,
left bundle branch block; PM, pacemaker; RBBB, right bundle branch block;
RBC, red blood cells; TIA, transient ischemic attack.
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confer a slight advantage in terms of patient comfort and lower
incidence of secondary safety outcomes.
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